biotech / news / / The Clinical Trial Vanguard
The RC48-C016 trial drove China’s NMPA approval of toripalimab plus disitamab vedotin for first-line HER2-expressing urothelial carcinoma.
The RC48-C016 trial showed toripalimab plus disitamab vedotin nearly doubled PFS and OS versus chemotherapy.
KEY POINTS
- The trial defined HER2 expression broadly as IHC 1+, 2+, or 3+, enlarging the eligible patient population.
- Disitamab vedotin plus toripalimab demonstrated a 76.1% ORR versus 50.2%, with response duration tripling to 14.6 months.
- Toripalimab's unique promotion of PD-1 receptor internalization may contribute to enhanced synergistic efficacy.
- The broad HER2 threshold used may face additional scrutiny if RemeGen and Junshi seek FDA approval.
COMPANIES
Summarized by Newsio from The Clinical Trial Vanguard. How we summarize →